Orion Clinical Services
Orion Clinical Services is recorded as a service provider in 9 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 9 of 9 trials · Latest update first
HELIOS: An Open-Label, Long-Term Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP).
Sponsor Disc Medicine Inc.
- Start (EU)
- Latest update
- Estimated end
An Open-Label, Phase 1 Dose-finding Study to Define the Maximum Tolerated Dose and Schedule of TRP-001 as Neoadjuvant Therapy in Treatment-naïve Very High-Risk Prostate Cancer Patients Eligible for Radical Prostatectomy with Extended Pelvic Lymph Node Dissection
Sponsor Torpedo Pharmaceuticals AG
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
A Phase I/IIa, open-label, dose finding, safety, tolerability and exploratory trial of THEO-260 in patients with high grade serous or endometrioid ovarian cancer
Sponsor Theolytics Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 2a, open-label, randomized, controlled, multi-center, proof of concept study, to assess the efficacy, safety, and tolerability of VS-01 on top of standard of care, compared to standard of care alone, in adult patients with acute-on-chronic liver failure (ACLF)
Sponsor Versantis AG
- Start (EU)
- Latest update
- Estimated end
A Phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, pharmacodynamic markers, and pharmacokinetics of AP-101 in patients with familial amyotrophic lateral sclerosis (fALS) and sporadic amyotrophic lateral sclerosis (sALS)
Sponsor AL-S Pharma AG
- Start (EU)
- Latest update
- Estimated end
Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2002 in Adults with Hereditary Angioedema (HAE)
Sponsor Intellia Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Long-Term Follow-Up of Subjects Treated With NTLA-2002
Sponsor Intellia Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase IIb, Open-label, Randomized Study of Nab-Paclitaxel and Gemcitabine plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer (VIRAGE)
Sponsor Theriva Biologics S.L.
- Start (EU)
- Latest update
- Estimated end
A Modular, Multipart, Multi-arm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of EP0042 Alone and in Combination with Anti-cancer Treatments in Patients with Advanced Malignancies.
Sponsor Ellipses Pharma Limited
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Orion Clinical Services?
The 2026-10-09 snapshot links Orion Clinical Services to 9 distinct CTIS trials. Recorded services include Clinical monitoring, Medical writing, Investigator recruitment, Regulatory services, among 16 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Orion Clinical Services?
The most frequently recorded therapeutic areas are Dermatology, Genetic and Congenital Disorders, Gynecology, Metabolic Disorders. Recorded phases include Phase 1, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Orion Clinical Services conducted?
The linked trials record locations in 10 countries, including Germany, Spain, France, Netherlands, Belgium. These are trial locations, not confirmed office locations or countries where Orion Clinical Services delivered services.
What can this page tell me about Orion Clinical Services's trial experience?
Browse 9 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Orion Clinical Services. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Orion Clinical Services Limited